ANGO

AngioDynamicsA

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$21.00

Analysis reference price unavailable

Analysis 2026-09-13 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$17.00

Analysis reference price unavailable

Analysis 2026-09-13 · RankAlpha Sentiment Codex

B-

Bear case

20%

Probability

Target price

$11.00

Analysis reference price unavailable

Analysis 2026-09-13 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-13

AI commentary

Primary filing evidence is constructive on Med Tech growth, profitability progress, reimbursement, and clinical milestones. Stored third-party coverage reported that shares gained about 8.9% during the month following earnings, although the immediate after-hours reaction was flat. No reliable social, options-skew, short-interest, employee-sentiment, or post-earnings analyst-revision data were supplied; the zero sentiment fields therefore indicate unavailable inputs rather than neutral readings. With the shares already above the July insider-sale prices and forward adoption evidence still limited, sentiment supports cautious monitoring rather than a high-conviction upgrade.

RankAlpha Sentiment Codex - 2026-09-13

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2027-05-31eventNanoKnife reimbursement and clinical executionHigh impact

The Medicare coverage determination for qualifying NanoKnife prostate and liver cancer procedures became effective July 5, 2026, while the company also reported IDE approvals and multiple trial initiations. Evidence of resulting hospital adoption, probe utilization, and continued trial execution could validate the commercial opportunity; specific readout timing was not supplied [#SEC-8K-2026-07-14].

2027-05-31catalystGrowth fails to produce consistent profitabilityHigh impact

Fourth-quarter adjusted loss was $0.07 per share, Med Device revenue grew only 1.1% pro forma, and management cited tariff-related headwinds. Slower Med Tech momentum or inadequate operating leverage could reverse the post-earnings rerating [#SEC-8K-2026-07-14].

2027-05-31catalystMed Tech growth converts into durable operating leverageHigh impact

Fiscal 2026 Med Tech sales grew 18.4% pro forma, adjusted EBITDA reached $13.2 million, and year-end cash was $53.9 million. Sustained Auryon and NanoKnife growth with further margin improvement could support a higher valuation, but the thesis remains dependent on execution by a low-coverage small-cap issuer [#SEC-8K-2026-07-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-13 • Updated nightlySource: Internal modelMethodology